Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Arrowhead Pharmaceuticals has dosed the first participant in the Phase I/IIa AROALK7-1001 trial of ARO-ALK7, an ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer.

The expression of symptoms of viral infections is a byproduct of complex virus-host molecular pathways. These remain largely ...

Adding zilebesiran to a thiazide diuretic or calcium channel blocker may lead to further blood pressure reduction in patients with uncontrolled hypertension. Zilebesiran added to hypertension ...

Several genetic studies have attempted to explore the fungal factors involved in antiviral responses, but the exact genes and ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

The molecular pathways involved in antiviral defenses and counter-defenses in host-pathogen systems remain unclear. Researchers have used Neurospora crassa as a model organism to explore how RNA ...